
Celyad is a biotechnology business based in the US. Celyad shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad employs 95 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Celyad stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CYAD. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Celyad stock price (NASDAQ: CYAD)
Use our graph to track the performance of CYAD stocks over time.Celyad shares at a glance
Latest market close | $1.29 |
---|---|
52-week range | $0.46 - $3.65 |
50-day moving average | $0.99 |
200-day moving average | $1.57 |
Wall St. target price | $8.52 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.51 |
Buy Celyad stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Celyad stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Celyad price performance over time
Historical closes compared with the close of $1.29 from 2023-01-27
1 week (2023-01-24) | -19.88% |
---|---|
1 month (2022-12-30) | 161.66% |
3 months (2022-10-31) | 22.86% |
6 months (2022-07-29) | -24.56% |
1 year (2022-01-31) | -63.25% |
---|---|
2 years (2021-01-29) | -84.00% |
3 years (2020-01-31) | 10.8 |
5 years (2018-01-30) | 47.52 |
Celyad financials
Gross profit TTM | $5,000 |
---|---|
Return on assets TTM | -29.33% |
Return on equity TTM | -92.64% |
Profit margin | 0% |
Book value | $1.36 |
Market capitalisation | $37.2 million |
TTM: trailing 12 months
Celyad share dividends
We're not expecting Celyad to pay a dividend over the next 12 months.
Celyad share price volatility
Over the last 12 months, Celyad's shares have ranged in value from as little as $0.46 up to $3.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad's is 0.8992. This would suggest that Celyad's shares are less volatile than average (for this exchange).
Celyad overview
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .
Frequently asked questions
What percentage of Celyad is owned by institutions?Currently 29.127% of Celyad shares are held by institutions. How many people work for Celyad?
Latest data suggests 95 work at Celyad. When does the fiscal year end for Celyad?
Celyad's fiscal year ends in December. Where is Celyad based?
Celyad's address is: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435 What is Celyad's ISIN number?
Celyad's international securities identification number is: US1512052002 What is Celyad's CUSIP number?
Celyad's Committee on Uniform Securities Identification Procedures number is: 151205200
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert